206 related articles for article (PubMed ID: 11566973)
1. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens.
Hammerschlag MR; Roblin PM; Bébéar CM
J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():25-31. PubMed ID: 11566973
[TBL] [Abstract][Full Text] [Related]
2. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
Felmingham D; Zhanel G; Hoban D
J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
[TBL] [Abstract][Full Text] [Related]
3. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
4. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of new antibacterial therapies in at-risk populations.
Lorenz J
J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
[TBL] [Abstract][Full Text] [Related]
6. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
Lorenz J
Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
[TBL] [Abstract][Full Text] [Related]
7. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
[TBL] [Abstract][Full Text] [Related]
8. Microbiological profile of telithromycin, the first ketolide antimicrobial.
Felmingham D
Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558
[TBL] [Abstract][Full Text] [Related]
9. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
[TBL] [Abstract][Full Text] [Related]
10. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
Yassin HM; Dever LL
Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
[TBL] [Abstract][Full Text] [Related]
11. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin.
Leclercq R
J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():9-23. PubMed ID: 11566972
[TBL] [Abstract][Full Text] [Related]
12. The ketolides: a critical review.
Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ
Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046
[TBL] [Abstract][Full Text] [Related]
13. Tissue kinetics of telithromycin, the first ketolide antibacterial.
Muller-Serieys C; Andrews J; Vacheron F; Cantalloube C
J Antimicrob Chemother; 2004 Feb; 53(2):149-57. PubMed ID: 14729764
[TBL] [Abstract][Full Text] [Related]
14. Ketolides in the treatment of respiratory infections.
Zhanel GG; Hoban DJ
Expert Opin Pharmacother; 2002 Mar; 3(3):277-97. PubMed ID: 11866679
[TBL] [Abstract][Full Text] [Related]
15. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Carter PL
Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
[TBL] [Abstract][Full Text] [Related]
16. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting.
Clark JP; Langston E
Mayo Clin Proc; 2003 Sep; 78(9):1113-24. PubMed ID: 12962166
[TBL] [Abstract][Full Text] [Related]
17. Telithromycin: an oral ketolide for respiratory infections.
Bearden DT; Neuhauser MM; Garey KW
Pharmacotherapy; 2001 Oct; 21(10):1204-22. PubMed ID: 11601667
[TBL] [Abstract][Full Text] [Related]
18. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.
Hammerschlag MR; Sharma R
Expert Opin Investig Drugs; 2008 Mar; 17(3):387-400. PubMed ID: 18321237
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
Kohno S; Hoban D;
J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
[TBL] [Abstract][Full Text] [Related]
20. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
